GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 3, 2007, Pages 1032-1045

  Medhurst, Andrew D ^a   Atkins, Alan R ^a   Beresford, Isabel J ^a   Brackenborough, Kim ^a   Briggs, Michael A ^a   Calver, Andrew R ^a   Cilia, Jackie ^a   Cluderay, Jane E ^a   Crook, Barry ^a   Davis, John B ^a   Davis, Rebecca K ^a   Davis, Robert P ^a   Dawson, Lee A ^a   Foley, Andrew G ^c   Gartlon, Jane ^a   Gonzalez, M Isabel ^a   Heslop, Teresa ^a   Hirst, Warren D ^a   Jennings, Carol ^a   Jones, Declan N C ^a   Lacroix, Laurent P ^a   Martyn, Abbe ^a   Ociepka, Sandrine ^a   Ray, Alison ^a   Regan, Ciaran M ^c   Roberts, Jennifer C ^a   Schogger, Joanne ^a   Southam, Eric ^a   Stean, Tania O ^a   Trail, Brenda K ^a   Upton, Neil ^a   Wadsworth, Graham ^a   Wald, Jeffrey A ^b   White, Trevor ^a   Witherington, Jason ^a   Woolley, Marie L ^a   Worby, Angela ^a   Wilson, David M ^a   more..

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CYANOPHENYL) 2 [2 (2 METHYL 1 IMIDAZOLIDINYL)ETHYL]BENZOFURAN; 6 [(3 CYCLOBUTYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 YL)OXY] N METHYL 3 PYRIDINECARBOXAMIDE; ACETYLCHOLINE; ALPHA METHYL[IMIDAZOLE 2,5(N) HISTAMINE; ALPHA METHYLHISTAMINE; CIPROXIFAN; CLOBENPROPIT; DOPAMINE; GSK 189254; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; MEPYRAMINE; NORADRENALIN; PROTEIN C FOS; THIOPERAMIDE; UNCLASSIFIED DRUG; ZOLANTIDINE; 6 ((3 CYCLOBUTYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 YL)OXY) N METHYL 3 PYRIDINECARBOXAMIDE; 6-((3-CYCLOBUTYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPIN-7-YL)OXY)-N-METHYL-3-PYRIDINECARBOXAMIDE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTIHISTAMINIC AGENT; BENZAZEPINE DERIVATIVE; DRUG DERIVATIVE; HISTAMINE AGONIST; NICOTINAMIDE; NOOTROPIC AGENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN CORTEX; COGNITION; CONTROLLED STUDY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG STRUCTURE; HIPPOCAMPUS; HUMAN; HUMAN CELL; IC 50; IMMUNOREACTIVITY; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SOMATOSENSORY CORTEX; ADOLESCENT; ADULT; AGED; ANIMAL; BINDING COMPETITION; BRAIN; CELL LINE; DOG; DRUG EFFECT; MAZE TEST; METABOLISM; MIDDLE AGED; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; SWINE; WISTAR RAT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; BENZAZEPINES; BINDING, COMPETITIVE; BRAIN; CELL LINE; DOGS; HISTAMINE AGONISTS; HISTAMINE ANTAGONISTS; HUMANS; MALE; MAZE LEARNING; MICE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; NIACINAMIDE; NOOTROPIC AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, HISTAMINE H3; SUS SCROFA;

EID: 34248562939     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.120311     Document Type: Article

References (42)

1. Anichtchik OV, Peitsaro N, Rinne JO, Kalimo H, and Panula P (2001) Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease. Neurobiol Dis 8:707-716.
2. Arrang JM, Garbarg M, and Schwartz JC (1983) Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature (Lond) 302:832-837.
3. Bamford MJ, Dean DK, Sehmi SS, Wilson DM, and Witherington J (2004) inventors; Glaxo Group Limited, assignees. Benzodiazepine derivatives for the treatment of neurological disorders. World patent WO 2004/056369 A1. 2004 Jul 8.
4. Barbier AJ, Berridge C, Dugovic C, Laposky AD, Wilson SJ, Boggs J, Aluisio L, Lord B, Mazur C, Pudiak CM, et al. (2004) Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol 143:649-661.
5. Blandina P, Giorgetti M, Bartolini L, Cecchi M, Timmerman H, Leurs R, Pepeu G, and Giovannini MG (1996) Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats. Br J Pharmacol 119: 1656-1664.
6. Brown RE, Stevens DR, and Haas HL (2001) The physiology of brain histamine. Prog Neurobiol 63:637-672.
7. Celanire S, Wijtmans M, Talaga P, Leurs R, and de Esch IJ (2005) Keynote review: histamine H3 receptor antagonists reach out for the clinic. Drug Discov Today 10:1613-1627.
8. Chen J, Liu C, and Lovenberg TW (2003) Molecular and pharmacological characterization of the mouse histamine H3 receptor. Eur J Pharmacol 467:57-65.
9. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
10. Clapham J and Kilpatrick GJ (1993) Histamine H3 receptor-mediated modulation of water consumption in the rat. Eur J Pharmacol 232:99-103.
11. Condreay JP, Witherspoon SM, Clay WC, and Kost TA (1999) Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector. Proc Natl Acad Sci USA 96:127-132.
12. Corey-Bloom J (2002) The ABC of Alzheimer's disease: cognitive changes and their management in Alzheimer's disease and related dementias. Int Psychogeriatr 14 (Suppl 1):51-75.
13. Ennaceur A and Delacour J (1988) A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 31:47-59.
14. Esbenshade TA, Fox GB, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan L, Wetter J, et al. (2005) Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile] : I. Potent and selective histamine H3 receptor antagonist with drug-like properties. J Pharmacol Exp Ther 313:165-175.
15. Esbenshade TA, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Fox GB, Faghih R, Bennani YL, et al. (2003) Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects. J Pharmacol Exp Ther 305:887-896.
16. Foley AG, Murphy KJ, Hirst WD, Gallagher HC, Hagan JJ, Upton N, Walsh FS, and Regan CM (2004) The 5-HT(6) receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology 29:93-100.
17. Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, et al. (2005) Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl) benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther 313:176-190.
18. Fox GB, Pan JB, Radek RJ, Lewis AM, Bitner RS, Esbenshade TA, Faghih R, Bennani YL, Williams M, Yao BB, et al. (2003) Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J Pharmacol Exp Ther 305:897-908.
19. Hancock AA, Blitner RS, Krueger KM, Otte S, Nikkel AL, Fey TA, Bush EN, Dickinson RW, Shapiro R, Knourek-Segel VE, et al. (2006) Distinctions and contradistinctions between antiobesity histamine H3 receptor (H3R) antagonists compared to cognition-enhancing H3 receptor antagonists. Inflamm Res 55 (Suppl 1):S42-S44.
20. Hancock AA and Fox GB (2004) Perspectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin Investig Drugs 13:1237-1248.
21. Hatcher PD, Brown VJ, Tait DS, Bate S, Overend P, Hagan JJ, and Jones DN (2005) 5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats. Psychopharmacology (Berl) 181:253-259.
22. Howlett DR, Richardson JC, Austin A, Parsons AA, Bate ST, Davies DC, and Gonzalez MI (2004) Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res 1017:130-136.
23. Hughes ZA and Dawson LA (2004) Differential autoreceptor control of extracellular 5-HT in guinea pig and rat: species and regional differences. Psychopharmacology (Berl) 172:87-93.
24. Jennings CA, Cluderay JE, Gartlon J, Cilia J, Lloyd A, Jones DN, and Southam E (2006) The effects of ziprasidone on regional c-Fos expression in the rat forebrain. Psychopharmacology (Berl) 184:13-20.
25. Johnson CN, Roland A, and Upton N (2004) New symptomatic strategies in Alzheimer's disease. Drug Discov Today 1:13-19.
26. Lacroix LP, Dawson LA, Hagan JJ, and Heidbreder CA (2004) 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex. Synapse 51:158-164.
27. Leurs R, Bakker RA, Timmerman H, and de Esch IJ (2005) The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov 4:107-120.
28. Ligneau X, Morisset S, Tardivel-Lacombe J, Gbahou F, Ganellin CR, Stark H, Schunack W, Schwartz JC, and Arrang JM (2000) Distinct pharmacology of rat and human histamine H(3) receptors: role of two amino acids in the third trans-membrane domain. Br J Pharmacol 131:1247-1250.
29. Lovenberg TW, Pyati J, Chang H, Wilson SJ, and Erlander MG (2000) Cloning of rat histamine H(3) receptor reveals distinct species pharmacological profiles. J Pharmacol Exp Ther 293:771-778.
30. Lovenberg TW, Roland BL, Wilson SJ, Jiang X, Pyati J, Huvar A, Jackson MR, and Erlander MG (1999) Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 55:1101-1107.
31. Martinez-Mir MI, Pollard H, Moreau J, Arrang JM, Ruat M, Traiffort E, Schwartz JC, and Palacios JM (1990) Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates. Brain Res 526:322-327.
32. 3 receptors in human brain and improved cognitive performance in rats, in 10th International Conference on Alzheimer's Disease and Related Disorders; 2006 Jul; Madrid, Spain. Alzheimer's Association, Chicago, IL.
33. Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H, Schunack W, Ganellin CR, Schwartz JC, and Arrang JM (2000) High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature (Lond) 408:860-864.
34. Nakamura T, Itadani H, Hidaka Y, Ohta M, and Tanaka K (2000) Molecular cloning and characterization of a new human histamine receptor, HH4R. Biochem Biophys Res Commun 279:615-620.
35. Pan JB, Yao BB, Miller TR, Kroeger PE, Bennani YL, Komater VA, Esbenshade TA, Hancock AA, Decker MW, and Fox GB (2006) Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121. Life Sci 79:1366-1379.
36. Passani MB, Lin JS, Hancock A, Crochet S, and Blandina P (2004) The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 25:618-625.
37. Paxinos G and Watson C (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego.
38. Pollard H, Moreau J, Arrang JM, and Schwartz JC (1993) A detailed autoradiographic mapping of histamine H3 receptors in rat brain areas. Neuroscience 52:169-189.
39. 3H]Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 (VR-1) protein distribution. Brain Res 995:176-183.
40. Schlicker E and Kathmann M(1998) Modulation of in vitro neurotransmission in the CNS and in the retina via H3 heteroreceptors, in The Histamine H3 Receptor: A Target for New Drugs (Leurs R and Timmerman H eds) pp 13-26, Elsevier, Amsterdam, The Netherlands.
41. 3 receptor antagonists, in 13th Royal Society of Chemistry-Society of Chemical Industry Medicinal Chemistry Symposium; 2005 Sept; Cambridge, UK. Royal Society of Chemistry - Society of Chemical Industry, Cambridge, UK.
42. Witkin JM and Nelson DL (2004) Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol Ther 103:1-20.